As a world leader in the healthcare industry, Bristol-Myers Squibb has secured its market share with strong R&D efforts and its extensive co-operative relationships in many countries. It has recently made an investment of $60 million in its China endeavor with a new manufacturing facility near Shanghai, after entering the China market about 20 years ago. We interviewed Peter Dolan, CEO of Bristol-Myers Squibb, about his company’s renewed development efforts and the market outlook in China. A new product will be launched in the near future for treating hepatitis-B, pending regulatory approval.